SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is facing significant volatility as investors weigh the impact of potential memory-compression algorithms against the reality of long-term AI demand. While some in the community are aggressively buying the dip, others are citing macro concerns related to the conflict in the Middle East and energy costs, leading to a clash between institutional selling and retail bottom-fishing.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

Fannie Mae is capturing market attention as prominent investors like Bill Ackman and Michael Burry reinforce their bullish thesis on the stock's potential for a significant valuation uplift. The community is actively debating the timing of a potential release from government conservatorship, with many viewing recent volatility as a strategic opportunity to build positions amid ongoing speculation about political catalysts and policy shifts.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is under intense focus as investors weigh upcoming earnings alongside the company's long-term strategic pivot toward domestic magnet manufacturing and its partnership with the Department of Defense. Community sentiment remains polarized, with bullish investors highlighting the stock's role in U.S. supply chain independence and recent facility expansion, while others express frustration over recent price volatility and high-volume selling pressure.

Applied Digital Corporation

Applied Digital is experiencing intense volatility as investors weigh the company's long-term potential in AI infrastructure against macro-driven sell-offs linked to geopolitical tensions and debt concerns. While the community remains divided between those panic-selling and those adding to their positions, sentiment is heavily focused on the anticipation of new hyperscaler lease announcements as the primary catalyst for a recovery.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana Co. is facing significant volatility following a board-approved 5-for-1 forward stock split, a move investors are interpreting as an attempt to boost retail accessibility and liquidity amid skepticism over the company's long-term fundamentals. The community remains deeply divided, with vocal bears pointing to concerns over subprime loan exposure and potential accounting practices, while some bulls advocate for a rebound based on historical momentum and speculative positioning.

Maul Coin

Maul Coin is generating buzz as the community rallies around its recent launch and actively pushes for social media visibility to drive momentum following earlier volatility.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy Corp

Bloom Energy is currently rallying toward new highs as the market increasingly views its on-site power solutions as a critical 'bring-your-own-power' fix for AI data centers facing grid capacity constraints. While some investors are cautioning about potential overvaluation after a rapid run-up, the community remains heavily focused on the company's massive backlog and the strategic importance of its fuel cell technology in the ongoing AI infrastructure buildout.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientific is currently trending as investors weigh the company's long-term growth driven by innovations in electrophysiology and the WATCHMAN FLX device against recent market volatility and analyst concerns regarding valuation premiums. The community is actively debating the stock's stability, with many highlighting the stock as a prime candidate for accumulation on dips while others express frustration over recent price action.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is facing intense market volatility as investors weigh the company's long-term foundry expansion against broader geopolitical instability and semiconductor supply chain constraints. While some traders are capitalizing on rapid price swings and rumors of potential fab deals, the community remains divided between those betting on a manufacturing-led turnaround and those bracing for further downside amid macroeconomic uncertainty.

Free Bird

Free Bird is gaining traction as community members highlight the asset's structural consistency and market resilience amid broader cryptocurrency volatility. Enthusiasts are actively rallying behind the token, framing participation as a display of patriotic sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

United Therapeutics (NASDAQ:UTHR) Shares Gap Up Following Analyst Upgrade

United Therapeutics (NASDAQ:UTHR) Shares Gap Up After Analyst Upgrade...

Why Is United Therapeutics Stock Soaring Monday?

United Therapeutics (UTHR) stock surges 16% premarket after Tyvaso meets primary endpoint in pivotal IPF study. Get the full breakdown.read more...

United Therapeutics (NASDAQ:UTHR) Stock Price Expected to Rise, TD Cowen Analyst Says

TD Cowen lifted their target price on United Therapeutics from $575.00 to $660.00 and gave the company a "buy" rating in a research report on Monday...

<ul class="summary-bullets"><li>Nebulized Tyvaso improved absolute forced vital capacity (FVC) by 130.1 mL over placebo.</li><li>Consistent benefits were observed across patient subgroups regardless of background therapy, smoking status, or supplemental oxygen use.</li><li>Integrated analyses combining TETON-1 and TETON-2 reinforced Tyvaso’s effectiveness, showing a 111.8 mL FVC improvement.</li></ul>United Therapeutics Corp. (UTHR) announced on Monday that its TETON-1 trial of nebulized Tyvaso in the treatment of idiopathic pulmonary fibrosis (IPF) achieved its primary goal.The treatment not only met its main efficacy endpoint but also reduced the risk of clinical worsening.<h2 class="st-heading-2">Nebulized Tyvaso Shows Broad Efficacy</h2>The therapy demonstrated improvement in absolute forced vital capacity (FVC), outperforming placebo by 130.1 mL from baseline to week 52, giving new hope for patients with the debilitating lung disease.Benefits were consistent across subgroups, regardless of background therapy, smoking status, or supplemental oxygen use, while safety profiles aligned with previous Tyvaso studies, with no new adverse signals observed.<blockquote>“The unprecedented results of TETON-1, which surpassed even the overwhelmingly positive results of TETON-2, represent a profound step forward for people living with IPF, a devastating disease with few treatment options.”-Martine Rothblatt, Chairperson and CEO, United Therapeutics</blockquote>Following the update,&nbsp;<a href="https://stocktwits.com/symbol/UTHR">United Therapeutics’ stock</a> traded over 19% higher in Monday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ from ‘bearish’ territory the previous day. Message volume flipped to ‘high’ from ‘low’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">Integrated Analyses Strengthen Findings</h2>Combining data from TETON-1 and TETON-2 reinforced the therapy’s effectiveness, showing an improvement of 111.8 mL in FVC and consistent positive effects across most secondary endpoints.&nbsp;Overall survival trends favored Tyvaso. Following these results, United Therapeutics intends to submit a supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) by the end of summer 2026, seeking priority review to expand nebulized Tyvaso’s labeled indication to include IPF.UTHR stock has gained over 7% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-says-us-is-in-talks-with-new-iran-leadership-warns-complete-obliteration-of-energy-infrastructure-if-hormuz-remains-shut/cZERnXgRIZy">Trump Says US Is In Talks With ‘New’ Iran Leadership, Warns ‘Complete’ Obliteration Of Energy Infrastructure If Hormuz Remains Shut</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the United Therapeutics Corporation logo is seen displayed on a smartphone. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Did UTHR Stock Surge Over 19% Pre-Market Today? 

The company reported that its TETON-1 study to treat lung disease met its primary endpoint.

Equity

The company reported that its TETON-1 study to treat lung disease met its primary endpoint.


United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its TETON-1 study evaluating the use of nebulized Tyvaso for the treatment of idiopathic pulmonary fibrosis (IPF) met its primary efficacy endpoint, demonstrating superiority over placebo for the...

Pallas Capital Advisors LLC Boosts Stake in United Therapeutics Corporation $UTHR

Pallas Capital Advisors LLC raised its position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 147.6% during the fourth quarter, according to the company in its most recent 13F...

United Therapeutics Corporation $UTHR Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC grew its stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 88.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 26,960 shares of the biotechnology co...

United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Thursday, March 26th. The shares were sold at an average price of $535.81, for a total transaction of $5,090,195.00. Following the...

Wedge Capital Management L L P NC Has $29.57 Million Holdings in United Therapeutics Corporation $UTHR

Wedge Capital Management L L P NC lessened its holdings in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 8.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 60,6...

United Therapeutics Corporation $UTHR Shares Acquired by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC boosted its stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 123.7% during the fourth quarter, according to its most recent 13F filing...

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

United Therapeutics Corp

Fred Wilson - Union Square Ventures

Abigail Johnson - Fidelity

Jim Cramer - Media Personality

Josh Brown - Ritholtz Wealth Management

A lifetime achievement for industry titans. This honor is reserved for an individual whose groundbreaking contributions have shaped the investing landscape and how we engage with the markets.

Stocktwits

Stocktwits Polls

Positive trial results for the TETON-1 study show Tyvaso met primary endpoints for treating pulmonary fibrosis.

Current Price	$595.26
Prev Close	$522.83
Open	$604.09
Dividend Yield	0.00%
50-Day Moving Average	$495.92
Beta	0.46
Avg. Volume	376,933.71
PE Ratio	18.74

52-Week High	$549.50
52-Week Low	$266.98
Market Capitalization	$22.91B
EPS (Annual)	$27.86
Price to Book	3.22
Revenue Per Employee	$2.27M

UTHR
United Therapeutics Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest UTHR News

UTHRUnited Therapeutics Corp